articleAnnals of OncologyApr 18, 2019BRONZE OA

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

UAUrsula A. MatulonisRSRonnie Shapira‐FrommerADAlessandro D. SantinALAlla LisyanskayaSPSandro Pignata

Dana-Farber Cancer Institute · Dana-Farber/Harvard Cancer Center · +21 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

826
total citations
FWCI
39.52
Percentile
100%
References
29
Citations per year

Authors

21

Topics & keywords

Topics
Keywords
  • Medicine
  • Pembrolizumab
  • Ovarian cancer
  • Oncology
  • Internal medicine
  • Cancer
  • Phases of clinical research
  • Gynecology
No related works found for this paper.

Funding